RE:RE:RE:Sentinel pouches?
Really? Gosh I would have never known the pouches were not vascularized, if you had not pointed that out. You are my heerooo! Now for anybody else who understands science, we dont know how thoroughly the cells were vacularized and whether or not all of the islets survived. We know that the patient was not insulin independent so the staining of the sentinel cross sections might give us an early hint as to whether there was a cell dose or death issue. Before Red decided to try and educate me again. Yes islet cell survival was apparent from the data but islets are delicate. Actual data about the sentinels is important. And you want to bring up timing? Again, only an idiot tries to raise money in the summer, especially when very solid data on one patient and preliminary on another by October 5th is expected. Regardless of what we expect, the fact that management did this very early data is a big fat red flag. Or do you not follow that a .50 raise with a .75 warrant would have been less dilutive than .20/.30. Only time will tell but it sure looks like Bioteck was right about the rinse and repeat business. Anyone who bought shares in 2016/2017, Not to mention the 2016 investors in the pp have been diluted by close to 50% if all the warrants get exercised...nevermind the options.